Your Messages Inbox
Your Article Summary
See Latest ArticlesAmgen to collaborate with GSK to commercialize denosumab in Europe for postmenopausal osteoporosis
GlaxoSmithKline, 08/05/09
Amgen and GlaxoSmithKline announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis in Europe, Australia, New Zealand and Mexico once the product is approved in these countries. Amgen will commercialize the drug for PMO and oncology in the United States and Canada and for all oncology indications in Europe and specified markets.
Related Articles
Osteologix to Continue Development of Osteoporosis Drug
Internet Source, 10/21/09
Relevance Score: 93%
Lifestyle increases osteoporosis risk: docs
Internet Source, 10/21/09
Relevance Score: 90%
Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
Clinical Interventions in Aging, 11/12/09
Relevance Score: 89%
A microarray based identification of osteoporosis-related genes in primary culture of human osteoblasts
Bone, 10/27/09
Relevance Score: 89%
Evaluation of Compliance with Osteoporosis Treatment Guidelines After Initiation of a Pharmacist-Run Osteoporosis Service at a Family Medicine Clinic
Annals of Pharmacotherapy, 10/15/09
Relevance Score: 89%
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09
Harris Corp. Buys VA Contractor
HealthDataManagement, 11/23/09
Article Search
Sponsor